Archive


Category: ASCO 2022

  • ASCO22: J&J, Pfizer trade BCMA bispecific data in myeloma

    Johnson & Johnson and Pfizer both highlighted new data with BCMA-targeting bispecific antibodies in patients with relapsed or refractory multiple myeloma (RRMM) at ASCO, previewing a future rivalry if they get regulatory approval. J&J’s Janssen pharma division gave an update on its MajesTEC-1 study of teclistamab, its already-filed BCMAxCD3 bispecific, in RRMM patients who had […]

  • ASCO22: Enhertu aces key HER2-low test in breast cancer

    In February, AstraZeneca and Daiichi Sankyo teased the results of their pivotal trial of Enhertu in HER2-low breast cancer, and, at ASCO, they finally revealed the data – with the numbers every bit as good as hoped. The top-line results of DESTINY Breast-04 are impressive – in patients with HER2-low metastatic breast cancer who received […]

  • ASCO ’22 preview: Putting patients first

    For the first time since 2019, the American Society of Clinical Oncology (ASCO) annual meeting will be an in-person conference. We’re excited to re-connect with fellow oncology and clinical care professionals from across the globe to learn from one another and discuss key advances in cancer care and research. From innovations in cancer therapeutics to […]